1 Short‐term mortality |
67 |
|
Odds Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
1.1 Antibiotics versus control |
17 |
1058 |
Odds Ratio (M‐H, Fixed, 95% CI) |
0.81 [0.57, 1.15] |
1.2 Antioxidants versus control |
4 |
163 |
Odds Ratio (M‐H, Fixed, 95% CI) |
2.01 [0.53, 7.56] |
1.3 Aprotinin versus control |
7 |
651 |
Odds Ratio (M‐H, Fixed, 95% CI) |
0.68 [0.40, 1.14] |
1.4 Calcitonin versus control |
2 |
125 |
Odds Ratio (M‐H, Fixed, 95% CI) |
0.55 [0.15, 2.00] |
1.5 Cimetidine versus control |
1 |
40 |
Odds Ratio (M‐H, Fixed, 95% CI) |
1.0 [0.06, 17.18] |
1.6 EDTA versus control |
1 |
64 |
Odds Ratio (M‐H, Fixed, 95% CI) |
0.94 [0.12, 7.08] |
1.7 Gabexate versus control |
5 |
576 |
Odds Ratio (M‐H, Fixed, 95% CI) |
0.79 [0.48, 1.30] |
1.8 Glucagon versus control |
5 |
409 |
Odds Ratio (M‐H, Fixed, 95% CI) |
0.97 [0.51, 1.87] |
1.9 Iniprol versus control |
1 |
24 |
Odds Ratio (M‐H, Fixed, 95% CI) |
0.14 [0.01, 1.67] |
1.10 Lexipafant versus control |
3 |
423 |
Odds Ratio (M‐H, Fixed, 95% CI) |
0.55 [0.30, 1.01] |
1.11 Octreotide versus control |
5 |
927 |
Odds Ratio (M‐H, Fixed, 95% CI) |
0.76 [0.47, 1.23] |
1.12 Probiotics versus control |
2 |
358 |
Odds Ratio (M‐H, Fixed, 95% CI) |
1.70 [0.87, 3.30] |
1.13 Activated protein C versus control |
1 |
32 |
Odds Ratio (M‐H, Fixed, 95% CI) |
8.56 [0.41, 180.52] |
1.14 Somatostatin versus control |
6 |
493 |
Odds Ratio (M‐H, Fixed, 95% CI) |
0.57 [0.29, 1.10] |
1.15 Somatostatin plus omeprazole versus control |
1 |
140 |
Odds Ratio (M‐H, Fixed, 95% CI) |
0.23 [0.05, 1.11] |
1.16 Somatostatin plus ulinastatin versus control |
1 |
122 |
Odds Ratio (M‐H, Fixed, 95% CI) |
0.43 [0.15, 1.23] |
1.17 Thymosin versus control |
1 |
24 |
Odds Ratio (M‐H, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
1.18 Ulinastatin versus control |
1 |
132 |
Odds Ratio (M‐H, Fixed, 95% CI) |
0.45 [0.12, 1.72] |
1.19 Gabexate versus aprotinin |
2 |
298 |
Odds Ratio (M‐H, Fixed, 95% CI) |
0.62 [0.32, 1.20] |
1.20 Glucagon versus aprotinin |
1 |
134 |
Odds Ratio (M‐H, Fixed, 95% CI) |
1.33 [0.44, 4.08] |
1.21 Glucagon versus atropine |
1 |
150 |
Odds Ratio (M‐H, Fixed, 95% CI) |
4.17 [0.45, 38.21] |
1.22 Octreotide plus ulinastatin versus octreotide |
1 |
120 |
Odds Ratio (M‐H, Fixed, 95% CI) |
0.31 [0.06, 1.60] |
1.23 Somatostatin plus gabexate versus somatostatin |
1 |
252 |
Odds Ratio (M‐H, Fixed, 95% CI) |
0.93 [0.37, 2.33] |
1.24 Somatostatin plus ulinastatin versus somatostatin |
2 |
369 |
Odds Ratio (M‐H, Fixed, 95% CI) |
0.73 [0.34, 1.56] |
1.25 Somatostatin plus ulinastatin plus gabexate versus somatostatin |
1 |
238 |
Odds Ratio (M‐H, Fixed, 95% CI) |
0.61 [0.21, 1.74] |
1.26 Somatostatin plus ulinastatin versus somatostatin plus gabexate |
1 |
254 |
Odds Ratio (M‐H, Fixed, 95% CI) |
0.72 [0.26, 1.95] |
1.27 Somatostatin plus ulinastatin plus gabexate versus somatostatin plus gabexate |
1 |
246 |
Odds Ratio (M‐H, Fixed, 95% CI) |
0.65 [0.23, 1.86] |
1.28 Somatostatin plus ulinastatin plus gabexate versus somatostatin plus ulinastatin |
1 |
240 |
Odds Ratio (M‐H, Fixed, 95% CI) |
0.91 [0.30, 2.80] |
2 Serious adverse events (proportion) |
17 |
|
Odds Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
2.1 Antibiotics versus control |
5 |
304 |
Odds Ratio (M‐H, Fixed, 95% CI) |
0.65 [0.37, 1.15] |
2.2 Antioxidants versus control |
2 |
82 |
Odds Ratio (M‐H, Fixed, 95% CI) |
1.98 [0.48, 8.13] |
2.3 EDTA versus control |
1 |
64 |
Odds Ratio (M‐H, Fixed, 95% CI) |
0.52 [0.11, 2.39] |
2.4 Gabexate versus control |
2 |
201 |
Odds Ratio (M‐H, Fixed, 95% CI) |
1.31 [0.31, 5.60] |
2.5 Glucagon versus control |
2 |
127 |
Odds Ratio (M‐H, Fixed, 95% CI) |
0.29 [0.01, 7.46] |
2.6 Octreotide versus control |
1 |
58 |
Odds Ratio (M‐H, Fixed, 95% CI) |
1.73 [0.61, 4.93] |
2.7 Somatostatin versus control |
2 |
111 |
Odds Ratio (M‐H, Fixed, 95% CI) |
1.07 [0.35, 3.27] |
2.8 Gabexate versus aprotinin |
1 |
116 |
Odds Ratio (M‐H, Fixed, 95% CI) |
1.05 [0.22, 4.91] |
2.9 Ulinastatin versus gabexate |
1 |
62 |
Odds Ratio (M‐H, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
3 Serious adverse events (number) |
37 |
|
Rate Ratio (Fixed, 95% CI) |
Subtotals only |
3.1 Antibiotics versus control |
12 |
716 |
Rate Ratio (Fixed, 95% CI) |
0.86 [0.68, 1.07] |
3.2 Antioxidants versus control |
2 |
71 |
Rate Ratio (Fixed, 95% CI) |
0.22 [0.02, 2.21] |
3.3 Aprotinin versus control |
3 |
264 |
Rate Ratio (Fixed, 95% CI) |
0.79 [0.49, 1.29] |
3.4 Cimetidine versus control |
1 |
60 |
Rate Ratio (Fixed, 95% CI) |
1.0 [0.20, 4.95] |
3.5 EDTA versus control |
1 |
64 |
Rate Ratio (Fixed, 95% CI) |
0.94 [0.19, 4.65] |
3.6 Gabexate versus control |
3 |
375 |
Rate Ratio (Fixed, 95% CI) |
0.86 [0.64, 1.15] |
3.7 Glucagon versus control |
1 |
68 |
Rate Ratio (Fixed, 95% CI) |
1.0 [0.02, 50.40] |
3.8 Lexipafant versus control |
1 |
290 |
Rate Ratio (Fixed, 95% CI) |
0.67 [0.46, 0.96] |
3.9 Octreotide versus control |
4 |
770 |
Rate Ratio (Fixed, 95% CI) |
0.74 [0.60, 0.89] |
3.10 Probiotics versus control |
3 |
397 |
Rate Ratio (Fixed, 95% CI) |
0.94 [0.65, 1.36] |
3.11 Somatostatin versus control |
3 |
257 |
Rate Ratio (Fixed, 95% CI) |
1.03 [0.66, 1.59] |
3.12 Somatostatin plus omeprazole versus control |
1 |
140 |
Rate Ratio (Fixed, 95% CI) |
0.36 [0.19, 0.70] |
3.13 Somatostatin plus ulinastatin versus control |
1 |
122 |
Rate Ratio (Fixed, 95% CI) |
0.30 [0.15, 0.60] |
3.14 Glucagon versus atropine |
1 |
150 |
Rate Ratio (Fixed, 95% CI) |
0.33 [0.03, 3.20] |
3.15 Octreotide plus ulinastatin versus octreotide |
1 |
120 |
Rate Ratio (Fixed, 95% CI) |
0.30 [0.17, 0.51] |
3.16 Somatostatin plus ulinastatin versus somatostatin |
1 |
123 |
Rate Ratio (Fixed, 95% CI) |
0.28 [0.15, 0.56] |
4 Organ failure |
18 |
|
Odds Ratio (M‐H, Random, 95% CI) |
Subtotals only |
4.1 Antibiotics versus control |
5 |
258 |
Odds Ratio (M‐H, Random, 95% CI) |
0.78 [0.44, 1.38] |
4.2 Antioxidants versus control |
4 |
163 |
Odds Ratio (M‐H, Random, 95% CI) |
0.92 [0.39, 2.12] |
4.3 Gabexate versus control |
1 |
50 |
Odds Ratio (M‐H, Random, 95% CI) |
0.32 [0.01, 8.25] |
4.4 Lexipafant versus control |
2 |
340 |
Odds Ratio (M‐H, Random, 95% CI) |
0.68 [0.36, 1.27] |
4.5 Octreotide versus control |
2 |
430 |
Odds Ratio (M‐H, Random, 95% CI) |
0.51 [0.27, 0.97] |
4.6 Probiotics versus control |
2 |
358 |
Odds Ratio (M‐H, Random, 95% CI) |
0.80 [0.26, 2.47] |
4.7 Ulinastatin versus control |
1 |
129 |
Odds Ratio (M‐H, Random, 95% CI) |
0.27 [0.01, 6.67] |
4.8 Somatostatin plus gabexate versus somatostatin |
1 |
252 |
Odds Ratio (M‐H, Random, 95% CI) |
0.78 [0.33, 1.80] |
4.9 Somatostatin plus ulinastatin versus somatostatin |
1 |
246 |
Odds Ratio (M‐H, Random, 95% CI) |
0.58 [0.23, 1.45] |
4.10 Somatostatin plus ulinastatin plus gabexate versus somatostatin |
1 |
238 |
Odds Ratio (M‐H, Random, 95% CI) |
0.46 [0.17, 1.25] |
4.11 Somatostatin plus ulinastatin versus somatostatin plus gabexate |
1 |
254 |
Odds Ratio (M‐H, Random, 95% CI) |
0.75 [0.29, 1.92] |
4.12 Somatostatin plus ulinastatin plus gabexate versus somatostatin plus gabexate |
1 |
246 |
Odds Ratio (M‐H, Random, 95% CI) |
0.59 [0.21, 1.65] |
4.13 Somatostatin plus ulinastatin plus gabexate versus somatostatin plus ulinastatin |
1 |
240 |
Odds Ratio (M‐H, Random, 95% CI) |
0.79 [0.27, 2.35] |
5 Infected pancreatic necrosis |
15 |
|
Odds Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
5.1 Antibiotics versus control |
11 |
714 |
Odds Ratio (M‐H, Fixed, 95% CI) |
0.82 [0.53, 1.25] |
5.2 Octreotide versus control |
1 |
58 |
Odds Ratio (M‐H, Fixed, 95% CI) |
0.52 [0.04, 6.06] |
5.3 Probiotics versus control |
3 |
397 |
Odds Ratio (M‐H, Fixed, 95% CI) |
1.10 [0.62, 1.96] |
6 Sepsis |
11 |
|
Odds Ratio (M‐H, Random, 95% CI) |
Subtotals only |
6.1 Antibiotics versus control |
1 |
60 |
Odds Ratio (M‐H, Random, 95% CI) |
0.42 [0.11, 1.60] |
6.2 Aprotinin versus control |
2 |
103 |
Odds Ratio (M‐H, Random, 95% CI) |
1.84 [0.49, 6.96] |
6.3 Gabexate versus control |
3 |
373 |
Odds Ratio (M‐H, Random, 95% CI) |
1.10 [0.55, 2.19] |
6.4 Lexipafant versus control |
1 |
290 |
Odds Ratio (M‐H, Random, 95% CI) |
0.26 [0.08, 0.83] |
6.5 Octreotide versus control |
2 |
340 |
Odds Ratio (M‐H, Random, 95% CI) |
0.40 [0.05, 3.53] |
6.6 Probiotics versus control |
1 |
62 |
Odds Ratio (M‐H, Random, 95% CI) |
0.36 [0.10, 1.36] |
6.7 Gabexate versus aprotinin |
1 |
116 |
Odds Ratio (M‐H, Random, 95% CI) |
1.05 [0.22, 4.91] |
7 Adverse events (proportion) |
27 |
|
Odds Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
7.1 Antibiotics versus control |
6 |
429 |
Odds Ratio (M‐H, Fixed, 95% CI) |
0.51 [0.32, 0.80] |
7.2 Antioxidants versus control |
1 |
39 |
Odds Ratio (M‐H, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
7.3 Calcitonin versus control |
1 |
94 |
Odds Ratio (M‐H, Fixed, 95% CI) |
0.88 [0.12, 6.49] |
7.4 EDTA versus control |
1 |
64 |
Odds Ratio (M‐H, Fixed, 95% CI) |
0.79 [0.27, 2.31] |
7.5 Gabexate versus control |
3 |
373 |
Odds Ratio (M‐H, Fixed, 95% CI) |
0.83 [0.54, 1.27] |
7.6 Glucagon versus control |
2 |
127 |
Odds Ratio (M‐H, Fixed, 95% CI) |
0.09 [0.00, 1.69] |
7.7 Lexipafant versus control |
1 |
83 |
Odds Ratio (M‐H, Fixed, 95% CI) |
0.43 [0.16, 1.12] |
7.8 Octreotide versus control |
3 |
398 |
Odds Ratio (M‐H, Fixed, 95% CI) |
1.00 [0.65, 1.55] |
7.9 Probiotics versus control |
1 |
62 |
Odds Ratio (M‐H, Fixed, 95% CI) |
0.35 [0.12, 1.01] |
7.10 Somatostatin versus control |
2 |
111 |
Odds Ratio (M‐H, Fixed, 95% CI) |
0.44 [0.19, 1.02] |
7.11 Somatostatin plus omeprazole versus control |
1 |
140 |
Odds Ratio (M‐H, Fixed, 95% CI) |
0.00 [0.00, 0.04] |
7.12 Gabexate versus aprotinin |
2 |
298 |
Odds Ratio (M‐H, Fixed, 95% CI) |
0.41 [0.23, 0.70] |
7.13 Ulinastatin versus gabexate |
1 |
62 |
Odds Ratio (M‐H, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
7.14 Ulinastatin versus octreotide |
1 |
25 |
Odds Ratio (M‐H, Fixed, 95% CI) |
2.33 [0.46, 11.81] |
7.15 Somatostatin plus gabexate versus somatostatin |
1 |
252 |
Odds Ratio (M‐H, Fixed, 95% CI) |
0.93 [0.44, 1.95] |
7.16 Somatostatin plus ulinastatin versus somatostatin |
1 |
246 |
Odds Ratio (M‐H, Fixed, 95% CI) |
0.58 [0.25, 1.34] |
7.17 Somatostatin plus ulinastatin plus gabexate versus somatostatin |
1 |
238 |
Odds Ratio (M‐H, Fixed, 95% CI) |
0.49 [0.20, 1.20] |
7.18 Somatostatin plus ulinastatin versus somatostatin plus gabexate |
1 |
254 |
Odds Ratio (M‐H, Fixed, 95% CI) |
0.63 [0.27, 1.44] |
7.19 Somatostatin plus ulinastatin plus gabexate versus somatostatin plus gabexate |
1 |
246 |
Odds Ratio (M‐H, Fixed, 95% CI) |
0.53 [0.22, 1.28] |
7.20 Somatostatin plus ulinastatin plus gabexate versus somatostatin plus ulinastatin |
1 |
240 |
Odds Ratio (M‐H, Fixed, 95% CI) |
0.84 [0.32, 2.22] |
8 Adverse events (number) |
40 |
|
Rate Ratio (Random, 95% CI) |
Subtotals only |
8.1 Antibiotics versus control |
12 |
755 |
Rate Ratio (Random, 95% CI) |
0.75 [0.58, 0.95] |
8.2 Antioxidants versus control |
2 |
94 |
Rate Ratio (Random, 95% CI) |
0.82 [0.38, 1.79] |
8.3 Aprotinin versus control |
3 |
264 |
Rate Ratio (Random, 95% CI) |
0.98 [0.69, 1.39] |
8.4 Calcitonin versus control |
1 |
94 |
Rate Ratio (Random, 95% CI) |
0.88 [0.12, 6.25] |
8.5 Cimetidine versus control |
1 |
60 |
Rate Ratio (Random, 95% CI) |
1.14 [0.64, 2.02] |
8.6 EDTA versus control |
1 |
64 |
Rate Ratio (Random, 95% CI) |
0.63 [0.28, 1.39] |
8.7 Gabexate versus control |
3 |
375 |
Rate Ratio (Random, 95% CI) |
0.76 [0.61, 0.95] |
8.8 Glucagon versus control |
2 |
90 |
Rate Ratio (Random, 95% CI) |
1.19 [0.51, 2.80] |
8.9 Lexipafant versus control |
1 |
290 |
Rate Ratio (Random, 95% CI) |
0.61 [0.44, 0.85] |
8.10 Octreotide versus control |
4 |
634 |
Rate Ratio (Random, 95% CI) |
0.78 [0.58, 1.05] |
8.11 Probiotics versus control |
3 |
397 |
Rate Ratio (Random, 95% CI) |
0.84 [0.52, 1.36] |
8.12 Somatostatin versus control |
2 |
134 |
Rate Ratio (Random, 95% CI) |
0.75 [0.26, 2.18] |
8.13 Ulinastatin versus control |
1 |
129 |
Rate Ratio (Random, 95% CI) |
0.69 [0.32, 1.46] |
8.14 Gabexate versus aprotinin |
1 |
182 |
Rate Ratio (Random, 95% CI) |
0.66 [0.38, 1.14] |
8.15 Glucagon versus atropine |
1 |
150 |
Rate Ratio (Random, 95% CI) |
0.79 [0.36, 1.73] |
8.16 Oxyphenonium versus glucagon |
1 |
62 |
Rate Ratio (Random, 95% CI) |
0.93 [0.65, 1.34] |
8.17 Octreotide plus ulinastatin versus octreotide |
1 |
120 |
Rate Ratio (Random, 95% CI) |
0.29 [0.17, 0.48] |
9 Requirement for additional invasive intervention |
32 |
|
Odds Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
9.1 Antibiotics versus control |
14 |
884 |
Odds Ratio (M‐H, Fixed, 95% CI) |
0.82 [0.59, 1.13] |
9.2 Aprotinin versus control |
2 |
237 |
Odds Ratio (M‐H, Fixed, 95% CI) |
0.59 [0.23, 1.47] |
9.3 Calcitonin versus control |
2 |
125 |
Odds Ratio (M‐H, Fixed, 95% CI) |
0.30 [0.08, 1.16] |
9.4 Cimetidine versus control |
1 |
60 |
Odds Ratio (M‐H, Fixed, 95% CI) |
0.13 [0.01, 2.61] |
9.5 EDTA versus control |
1 |
64 |
Odds Ratio (M‐H, Fixed, 95% CI) |
0.68 [0.14, 3.29] |
9.6 Gabexate versus control |
3 |
426 |
Odds Ratio (M‐H, Fixed, 95% CI) |
0.58 [0.37, 0.90] |
9.7 Glucagon versus control |
2 |
260 |
Odds Ratio (M‐H, Fixed, 95% CI) |
1.26 [0.58, 2.77] |
9.8 Octreotide versus control |
3 |
854 |
Odds Ratio (M‐H, Fixed, 95% CI) |
0.76 [0.48, 1.21] |
9.9 Probiotics versus control |
2 |
358 |
Odds Ratio (M‐H, Fixed, 95% CI) |
1.50 [0.83, 2.71] |
9.10 Somatostatin versus control |
1 |
100 |
Odds Ratio (M‐H, Fixed, 95% CI) |
0.40 [0.11, 1.38] |
9.11 Gabexate versus aprotinin |
1 |
182 |
Odds Ratio (M‐H, Fixed, 95% CI) |
0.5 [0.19, 1.32] |
9.12 Glucagon versus aprotinin |
1 |
134 |
Odds Ratio (M‐H, Fixed, 95% CI) |
1.33 [0.44, 4.08] |
9.13 Oxyphenonium versus glucagon |
1 |
62 |
Odds Ratio (M‐H, Fixed, 95% CI) |
1.0 [0.13, 7.59] |
10 Endoscopic or radiological drainage of collections |
3 |
|
Odds Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
10.1 Antibiotics versus control |
1 |
23 |
Odds Ratio (M‐H, Fixed, 95% CI) |
0.33 [0.01, 9.07] |
10.2 Octreotide versus control |
1 |
372 |
Odds Ratio (M‐H, Fixed, 95% CI) |
0.89 [0.40, 1.96] |
10.3 Probiotics versus control |
1 |
39 |
Odds Ratio (M‐H, Fixed, 95% CI) |
0.94 [0.20, 4.44] |